Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/15/20 | Current report filing |
|
9 | ||
| 05/14/20 | Current report filing |
|
9 | ||
| 05/14/20 | SEC-generated letter |
|
1 | ||
| 05/13/20 | Current report filing |
|
37 | ||
| 05/13/20 | Current report filing |
|
8 | ||
| 05/07/20 | Current report filing |
|
3 | ||
| 05/07/20 | Registration statement for specified transactions by certain issuers |
|
33 | ||
| 05/04/20 | Prospectus filed pursuant to Rule 424(b)(5) |
|
62 | ||
| 05/04/20 | Current report filing |
|
8 | ||
| 04/17/20 | Definitive proxy statements |
|
60 |
